Literature DB >> 16010179

Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.

Homayoun Khanlou, Charles Farthing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16010179     DOI： 10.1097/01.qai.0000167477.20428.ce

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  5 in total

1.  Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

Authors:  Parya Saberi; Dilrini K Ranatunga; Charles P Quesenberry; Michael J Silverberg
Journal:  Pharmacotherapy       Date:  2011-03       Impact factor: 4.705

2.  In silico-assisted development of supersaturable preconcentrated isotropic mixture of atazanavir for augmenting biopharmaceutical performance in the presence of H2-receptor antagonist.

Authors:  Sheshank Sethi; Vikas Rana
Journal:  Drug Deliv Transl Res       Date:  2022-08-03       Impact factor: 5.671

3.  Atazanavir-Concentrate Loaded Soft Gelatin Capsule for Enhanced Concentration in Plasma, Brain, Spleen, and Lymphatics.

Authors:  Sheshank Sethi; Vikas Rana
Journal:  AAPS PharmSciTech       Date:  2022-09-28       Impact factor: 4.026

4.  Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.

Authors:  Hiba L Tappouni; John C Rublein; Brian J Donovan; Stephanie B Hollowell; Hsiao-Chuan Tien; Sherene S Min; Dickens Theodore; Naser L Rezk; Philip C Smith; Melanie N Tallman; Ralph H Raasch; Angela D M Kashuba
Journal:  Am J Health Syst Pharm       Date:  2008-03-01       Impact factor: 2.637

Review 5.  Drug interactions between HIV protease inhibitors and acid-reducing agents.

Authors:  Ronald W Falcon; Thomas N Kakuda
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.